155 related articles for article (PubMed ID: 34476778)
1. Multimodality imaging to distinguish between benign and malignant cardiac masses.
Aghayev A; Cheezum MK; Steigner ML; Mousavi N; Padera R; Barac A; Kwong RY; Di Carli MF; Blankstein R
J Nucl Cardiol; 2022 Aug; 29(4):1504-1517. PubMed ID: 34476778
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and staging of cardiac masses: additional value of CMR with
Mikail N; Males L; Hyafil F; Benali K; Deschamps L; Brochet E; Ehmer C; Driss AB; Saker L; Rossi A; Alkhoder S; Raffoul R; Rouzet F; Ou P
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2232-2241. PubMed ID: 35247063
[TBL] [Abstract][Full Text] [Related]
3. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
[TBL] [Abstract][Full Text] [Related]
4.
Qin C; Shao F; Hu F; Song W; Song Y; Guo J; Lan X
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1083-1093. PubMed ID: 31807883
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Accuracy of Cardiac Computed Tomography and 18-F Fluorodeoxyglucose Positron Emission Tomography in Cardiac Masses.
D'Angelo EC; Paolisso P; Vitale G; Foà A; Bergamaschi L; Magnani I; Saturi G; Rinaldi A; Toniolo S; Renzulli M; Attinà D; Lovato L; Lima GM; Bonfiglioli R; Fanti S; Leone O; Saponara M; Pantaleo MA; Rucci P; Di Marco L; Pacini D; Pizzi C; Galiè N
JACC Cardiovasc Imaging; 2020 Nov; 13(11):2400-2411. PubMed ID: 32563654
[TBL] [Abstract][Full Text] [Related]
6. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
7. Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue.
Krishnaraju VS; Kumar R; Mittal BR; Sharma V; Singh H; Nada R; Bal A; Rohilla M; Singh H; Rana SS
Eur Radiol; 2021 Apr; 31(4):2199-2208. PubMed ID: 33001304
[TBL] [Abstract][Full Text] [Related]
8. Combination of positron emission tomography/computed tomography and chest thin-layer high-resolution computed tomography for evaluation of pulmonary nodules: Correlation with imaging features, maximum standardized uptake value, and pathology.
Hou S; Lin X; Wang S; Shen Y; Meng Z; Jia Q; Tan J
Medicine (Baltimore); 2018 Aug; 97(31):e11640. PubMed ID: 30075545
[TBL] [Abstract][Full Text] [Related]
9. Solid splenic masses: evaluation with 18F-FDG PET/CT.
Metser U; Miller E; Kessler A; Lerman H; Lievshitz G; Oren R; Even-Sapir E
J Nucl Med; 2005 Jan; 46(1):52-9. PubMed ID: 15632034
[TBL] [Abstract][Full Text] [Related]
10. Improving the imaging diagnostic strategy for pulmonary artery masses based on
Hong C; Hou P; Chen HM; Zhong KX; Guo WL; Lin JL; Wu XF; Lei YX; Jia Q; Liu CL; Li SY; Wang XL
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4109-4121. PubMed ID: 35732973
[TBL] [Abstract][Full Text] [Related]
11. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET/CT in differentiating malignant from benign origins of obstructive jaundice.
Wang SB; Wu HB; Wang QS; Zhou WL; Tian Y; Ji YH; Lv L
Hepatobiliary Pancreat Dis Int; 2015 Oct; 14(5):516-22. PubMed ID: 26459728
[TBL] [Abstract][Full Text] [Related]
13. Differentiation between malignant and benign pathologic fractures with F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.
Shin DS; Shon OJ; Byun SJ; Choi JH; Chun KA; Cho IH
Skeletal Radiol; 2008 May; 37(5):415-21. PubMed ID: 18309481
[TBL] [Abstract][Full Text] [Related]
14. Incidental colonic focal FDG uptake on PET/CT: can the maximum standardized uptake value (SUVmax) guide us in the timing of colonoscopy?
van Hoeij FB; Keijsers RG; Loffeld BC; Dun G; Stadhouders PH; Weusten BL
Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):66-71. PubMed ID: 25139518
[TBL] [Abstract][Full Text] [Related]
15. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
16. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
17. Contribution and performance of multimodal imaging in the diagnosis and management of cardiac masses.
Lemasle M; Lavie Badie Y; Cariou E; Fournier P; Porterie J; Rousseau H; Petermann A; Hitzel A; Carrié D; Galinier M; Marcheix B; Lairez O
Int J Cardiovasc Imaging; 2020 May; 36(5):971-981. PubMed ID: 32040684
[TBL] [Abstract][Full Text] [Related]
18. Indirect comparison of the diagnostic performance of
Hu X; Li D; Liang Z; Liao Y; Yang L; Wang R; Wang P; Cai J
BMC Cancer; 2021 Oct; 21(1):1080. PubMed ID: 34615498
[TBL] [Abstract][Full Text] [Related]
19. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]